NuVision® are delighted to announce that they have signed a distribution agreement with Doctrinemed, a Turkish pharmaceutical and medical device company with a focus on ophthalmology. Doctrinemed will be working closely with NuVision in order to distribute our sight saving regenerative therapy, Omnigen® as well as OmniLenz® throughout Turkey.
Omnigen is a low temperature vacuum evaporated dry amniotic membrane regenerative therapy than can be used to effectively treat a variety of ocular surface disease and damage situations. Omnigen is easy to use, applied directly to the wound dry, for enhanced wound healing. OmniLenz is a bespoke contact lens specifically designed to deliver Omnigen regeneration in the treatment room without the need for complex surgery or sutures. Early and effective treatment of ocular surface damage will improve patient care and comfort, and ultimately help to save sight.
Doctrinemed was founded in 2018 by 3 entrepreneurs who have worked for over 10 years in the ophthalmology market at various corporate multinational companies. Recognising the need in the market for innovative treatment and diagnosis options, the team established Doctrinemed. Doctrinemed Team has strong expertise in Turkish ophthalmology market; which will be invaluable as they launch and open up access to Omnigen in their country. Doctrinemed are currently finalising regulatory approvals, and subsequently Omnigen and OmniLenz will expected to be available in the market early 2019.
The number of corneal injuries in Turkey due to disease as well as traffic accidents and security issues is significant. There are around 3500 ophthalmologists in the country yet previously there was no ‘ready to use’ amnion products available on the market. Omnigen will therefore deliver huge benefits to hospitals and clinics as they can treat patients with an accessible and readily available therapy.
NuVision is a UK-based regenerative company spun out from the University of Nottingham in 2015 established to translate many years of extensive amnion research into a clinically available and highly versatile regenerative therapy known as Omnigen. As a dry and stable product, Omnigen can be easily shipped, to be used or stored at the point of care.
Dr. Andrew Hopkinson the founder and CEO of NuVision said of the collaboration “We are excited to start working with the Doctinemed team to deliver the benefits of Omnigen to the people of Turkey. Omnigen was designed to be easily shipped and stored so that ophthalmologists anywhere in the world are equipped with the enhanced wound healing properties of Omnigen.”
Ökkeş Çetinkaya, National Sales Director, of Doctrinemed, stated “Omnigen is an innovative product which makes amnion therapy reachable and effective for everyone in Turkey regardless of the current limitations.”
The collaboration will bring together knowledge and experience from both parties. NuVision are excited to support Doctrinemed as they launch the product and are delighted that Omnigen is becoming available in more international markets.
To find out more, visit: www.nu-vision.co.uk